Head to Head Contrast: ProKidney (NASDAQ:PROK) & NKGen Biotech (NYSE:NKGN)

ProKidney (NASDAQ:PROK) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares ProKidney and NKGen Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-10.24%
NKGen Biotech	N/A	N/A	-479.36%

Valuation and Earnings

This table compares ProKidney and NKGen Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$35.47 million	($0.55)	-3.76
NKGen Biotech	$80,000.00	193.77	-$82.94 million	($5.08)	-0.09

ProKidney has higher earnings, but lower revenue than NKGen Biotech. ProKidney is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 41.5% of ProKidney shares are held by insiders. Comparatively, 74.7% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for ProKidney and NKGen Biotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0	3	2	0	2.40
NKGen Biotech	0	0	0	0	0.00

ProKidney presently has a consensus price target of $4.50, indicating a potential upside of 117.39%. Given ProKidney’s stronger consensus rating and higher probable upside, equities analysts plainly believe ProKidney is more favorable than NKGen Biotech.

Risk and Volatility

ProKidney has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500.

Summary

ProKidney beats NKGen Biotech on 7 of the 11 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.